Level Bio AB (FRA:4MB) Short-Term Debt: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4MB Level Bio AB FRA:4MB
23 GF Score
Price €0.02
! 4 Warning Signs
View Full Analysis

What is Level Bio AB Short-Term Debt?

Level Bio AB FRA:4MB 23 Short-Term Debt is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:4MB with a GF Score™ of 23/100. The stock has 4 warning signs investors should review.

Level Bio AB's Short-Term Debt for the quarter that ended in Mar. 2026 was €0.00 Mil.

Level Bio AB's quarterly Short-Term Debt increased from Sep. 2025 (€0.00 Mil) to Dec. 2025 (€0.15 Mil) but then declined from Dec. 2025 (€0.15 Mil) to Mar. 2026 (€0.00 Mil).

Level Bio AB's annual Short-Term Debt increased from Dec. 2023 (€0.10 Mil) to Dec. 2024 (€0.12 Mil) and increased from Dec. 2024 (€0.12 Mil) to Dec. 2025 (€0.15 Mil).

Level Bio AB Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Level Bio AB Short-Term Debt Related Terms

Level Bio AB Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Level Bio AB's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Level Bio AB Short-Term Debt Chart

Level Bio AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.03 0.10 0.12 0.15

Level Bio AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.15 0.00
FRA:4MB
23GF Score
Level Bio AB FRA:4MB
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €0.00 Mil mean?
Level Bio AB (FRA:4MB) has a Short-Term Debt of €0.00 Mil as of Mar. 2026.
Is Level Bio AB's Short-Term Debt too high?
Level Bio AB's current Short-Term Debt is €0.00 Mil. Overall, Level Bio AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Level Bio AB's Short-Term Debt compare to TMO and DHR?
Level Bio AB's Short-Term Debt of €0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Diagnostics & Research company?
A good Short-Term Debt depends on the Medical Diagnostics & Research industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Level Bio AB's current Short-Term Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Bio AB stock overvalued right now?
Level Bio AB (FRA:4MB) has a current Short-Term Debt of €0.00 Mil. The current Short-Term Debt is €0.00 Mil. Level Bio AB's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Level Bio AB (FRA:4MB), the current Short-Term Debt is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Level Bio AB Business Description

Other Exchanges LEVBIO:Sweden
Address Vastra Finnbodavagen 4B, Nacka, Stockholm, SWE, 131 30
Level Bio AB is a parent company and operates through subsidiary. It develops and manufactures diagnostic kits for the clinical market and also is a distributor and full service partner to molecular biology labs in the Nordics.
23GF Score

Get the complete analysis for FRA:4MB

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.02
Price